• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

DAS Role change

anonymous

Guest
You have probably heard that the DAS role is changing and that the DSM's are sworn to secrecy. Starting FQ2 DAS will only get paid on scripts that can be traced back to AS via ICD 10 code- sorry for those reps that have sold off label the 300mg dose. No credit. Requirements of a minimum of 12 disease state programs a year (1 per month). Will have a national market share goal component in bonus tracking competitor market share- Victor very upset that AS Share is eroding even though we are the newest product available. Also all DAS reps will report to a DSM that only has DAS reps so the entire Rheum team will be restructured- this way productivity can be better tracked (PSA and DAS) and performance plans will be issued for those that underperformed. Managers have tried to push back but Victor feels he knows what is best.

Next year they will also be tracking attendees at programs more closely and Victor wants to see more physicians at programs. Doesn't see the value in nurses and MA's that tend to dominate the attendee list.